Several analysts have recently updated their ratings and price targets for Curanex Pharmaceuticals (NASDAQ: CURX):
- 12/1/2025 – Curanex Pharmaceuticals had its “sell (e-)” rating reaffirmed by analysts at Weiss Ratings.
- 11/24/2025 – Curanex Pharmaceuticals had its “sell (e-)” rating reaffirmed by analysts at Weiss Ratings.
- 11/22/2025 – Curanex Pharmaceuticals was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
- 11/18/2025 – Curanex Pharmaceuticals is now covered by analysts at Weiss Ratings. They set a “sell (e-)” rating on the stock.
Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances.
Featured Articles
- Five stocks we like better than Curanex Pharmaceuticals
- 3 Dividend Kings To Consider
- Rubrik’s Massive Rebound: Why the Next Leg Higher Could Be Fast
- What is Short Interest? How to Use It
- Five Below and Dollar Tree Earnings Signal a Shopper Shift
- P/E Ratio Calculation: How to Assess Stocks
- Ulta’s Stock May Be Set for a Glow-Up—20% Upside Ahead?
Receive News & Ratings for Curanex Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curanex Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
